Opendata, web and dolomites

BabyLux

Launching the First Non-Invasive Brain-Monitoring System for the Early Detection and Management of Encephalopathy In Preterm Babies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BabyLux project word cloud

Explore the words cloud of the BabyLux project. It provides you a very rough idea of what is the project "BabyLux" about.

clinical    care    solving    maintaining    market    scientific    unsolved    photonic    monitoring    business    neonates    babies    until    born    segment    corroborate    tremendously    precise    first       over    leads    preterm    last    time    weeks    200m    sold    compilation    combining    million    live    premature    successful    commercialization    gestation    neonatal    lifelong    cerebral    solutions    damage    commercial    risk    techniques    births    anyhow    lasting    2014    sub    stage    accurate    oxygen    flow    partial    autism    failing    disorders    babylux    entrance    units    fall    easing    turnover    suffering    nicus    community    gestational    detect    20    months    blood    intensive    visual    requesting    invasive    gain    device    model    figures    13    manner    brain    credibility    markets    hospitals    paralysis    reaching    mixed    alive    fact    artificial    worldwide    15    deficit    hearing    37    impairments    assumptions    hemophotonics    period    metabolism    despite    smei    carg    segments    decades    encephalopathies    extremely    affordable   

Project "BabyLux" data sheet

The following table provides information about the project.

Coordinator
HEMOPHOTONICS SL 

Organization address
address: AVENIDA CARL FRIEDRICH GAUSS 3 OFICINA 346 MEDITERRANEAN TECHNOLOGY PARK
city: CASTELLDEFELS
postcode: 8860
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.hemophotonics.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HEMOPHOTONICS SL ES (CASTELLDEFELS) coordinator 50˙000.00

Map

 Project objective

Over the last two decades preterm babies (neonates with less than 37 weeks of gestational period) have rise tremendously reaching 15 million births worldwide in 2014, and the figures are growing. Anyhow, despite we have been successful at maintaining alive premature babies until their live it’s not at risk, we are failing at solving important side-problems. Preterm babies are at high risk of suffering encephalopathies (brain damage) during the artificial gestational stage on the neonatal intensive-care units (NICUs). In fact, about 20% of babies born before 6.5 months gestation experience lasting brain damage. This leads to lifelong disorders such as attention deficit, autism, cerebral paralysis, and hearing or visual impairments. To early detect cerebral damage in a precise manner it’s necessary to provide real time and accurate measures of cerebral oxygen metabolism and blood flow in the brain. This problem remains unsolved since current commercial solutions provide partial measurements or are extremely invasive. BabyLux will be the first device allowing early detect and manage encephalopathies in preterm-babies in a non-invasive and affordable manner by combining two leading photonic techniques. Our product fall within the sub-segment of “monitoring equipment” for NICUs, which is a € 1.200M market growing at a CARG of 6.5%.BabyLux will be sold at a first commercialization stage to pre-clinical markets (research institutions studying brain damage in neonates). We will proceed in such way since to gain credibility among scientific community, easing the entrance to clinical segments. At a second commercialization stage we will approach clinical segments, in particular hospitals with NICUs. This mixed business model will allow HemoPhotonics to achieve a turnover of € 13 M at 5 years after the project compilation. We are requesting a SMEI Phase 1 to further define and corroborate our business assumptions.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BABYLUX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BABYLUX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

MENTEE (2017)

MENTEE - Mastery learning in Europe through Technology Enhanced Education

Read More  

SOFT (2017)

SOFT, the first camera-based colorectal cancer screening test to detect occult blood in faeces immediately and with no lab analysis.

Read More  

Demographica (2017)

Helping marketing campaigns go viral

Read More